Replies to post #4463 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

[OT] >6% of patients receiving MACUGEN 0.3 mg (18/294) gained 3 15 letters of vision versus 2% of patients receiving usual care (6/296)<

I’m familiar with these figures (see #msg-1967290 from 2003), but some of the (few) patients who experienced improved vision in the trials were concomitantly treated with Visudyne.

>Macugen…may have a better safety profile for long term<

This is mostly OSIP propaganda that has now all but ceased.

>…the "first in" principle most likely helped to inform OSI in its disastrous acquisition of eyet<

Perhaps. But a more likely explanation, IMO, is that Eyetech’s David Guyer was a great salesman and OSIP’s Colin Goddard was a great sucker.